1,978 results on '"Olivotto, Iacopo"'
Search Results
52. Sudden cardiac death in cardiomyopathies: acting upon “acceptable” risk in the personalized medicine era
53. Creatine deficiency and heart failure
54. Abstract 16793: The Impact of Late Gadolinium Enhancement on Sudden Death Risk Stratification in Older Patients With Hypertrophic Cardiomyopathy
55. Abstract 14249: Sex and Gene Based Differences in Age Related Penetrance of Dilated and Arrhythmogenic Cardiomyopathy
56. Abstract 12733: The Effect of Mavacamten Treatment on Hemolysis Biomarkers in Patients With Obstructive Hypertrophic Cardiomyopathy in the EXPLORER-HCM Study
57. Abstract 12408: Response to Mavacamten by Sarcomere Gene Mutation Status in EXPLORER-HCM
58. Does a standard myectomy exist for obstructive hypertrophic cardiomyopathy? From the Morrow variations to precision surgery
59. Comparison of Demographic, Clinical, Biochemical, and Imaging Findings in Hypertrophic Cardiomyopathy Prognosis: A Network Meta-Analysis
60. Syncope in hypertrophic cardiomyopathy (part II): An expert consensus statement on the diagnosis and management
61. Safety and efficacy of ranolazine in hypertrophic cardiomyopathy: Real-world experience in a National Referral Center
62. Evaluation of stress myocardial blood flow patterns in patients with apical hypertrophic cardiomyopathy
63. Development of the Hypertrophic Cardiomyopathy Symptom Questionnaire (HCMSQ): A New Patient-Reported Outcome (PRO) Instrument
64. Pharmacological Management of Hypertrophic Cardiomyopathy: From Bench to Bedside
65. Impediments to Heart Transplantation in Adults With MELASMT-TL1:m.3243A>G Cardiomyopathy
66. Sudden death in young athletes: Is it preventable?
67. Acute Myocarditis Associated With Desmosomal Gene Variants
68. Left Ventricular Systolic Dysfunction in Patients Diagnosed With Hypertrophic Cardiomyopathy During Childhood: Insights From the SHaRe Registry
69. Sarcomere protein modulation: The new frontier in cardiovascular medicine and beyond
70. Diagnosis and Management of Rare Cardiomyopathies in Adult and Paediatric Patients. A Position Paper of the Italian Society of Cardiology (SIC) and Italian Society of Paediatric Cardiology (SICP)
71. Syncope in hypertrophic cardiomyopathy (part I): An updated systematic review and meta-analysis
72. Racial Differences in Val122Ile-Associated Transthyretin Cardiac Amyloidosis
73. Is heart failure with preserved ejection fraction a ‘dementia’ of the heart?
74. Slower Calcium Handling Balances Faster Crossbridge Cycling in Human MYBPC3 HCM
75. Clinical Features and Natural History of Preadolescent Nonsyndromic Hypertrophic Cardiomyopathy
76. Strength of clinical indication and therapeutic impact of the implantable cardioverter defibrillator in patients with hypertrophic cardiomyopathy
77. Factors associated with persistence of symptoms 1 year after COVID-19: A longitudinal, prospective phone-based interview follow-up cohort study
78. Cardiopulmonary Fitness and Personalized Exercise Prescription in Patients With Hypertrophic Cardiomyopathy.
79. The Influence of Genotype on the Phenotype, Clinical Course, and Risk of Adverse Events in Children with Hypertrophic Cardiomyopathy
80. Effect of Mavacamten on Echocardiographic Features in Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy
81. Subcutaneous implantable cardioverter-defibrillator and defibrillation testing: A propensity-matched pilot study
82. Long-term complications in patients implanted with subcutaneous implantable cardioverter-defibrillators: Real-world data from the extended ELISIR experience
83. Natural history and clinical outcomes of patients with hypertrophic cardiomyopathy from thin filament mutations
84. Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy
85. #2456 Real world outcomes of Fabry disease in Italian excellence centers: the ground study
86. Anderson–Fabry disease management: role of the cardiologist
87. S-ICD Implantation in Secondary Prevention in a Young Patient With Recent Surgically Repaired Pectus Excavatum
88. Genetic Tailoring of Electrophysiological Management in Hypertrophic Cardiomyopathy
89. Maximal Wall Thickness Measurement in Hypertrophic Cardiomyopathy: Biomarker Variability and its Impact on Clinical Care
90. Recognition of pre-hypertrophic cardiac involvement in Fabry Disease based on automated electrocardiographic measures
91. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
92. Combined Effect of Mediterranean Diet and Aerobic Exercise on Weight Loss and Clinical Status in Obese Symptomatic Patients with Hypertrophic Cardiomyopathy
93. Cardiac involvement in eosinophilic granulomatosis with polyangiitis (formerly Churg-Strauss syndrome): Prospective evaluation at a tertiary referral centre
94. Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study
95. The Italian Fabry Disease Cardiovascular Registry (IFDCR)
96. Pathophysiology and Treatment of Hypertrophic Cardiomyopathy: New Perspectives
97. Computational prediction of protein subdomain stability in MYBPC3 enables clinical risk stratification in hypertrophic cardiomyopathy and enhances variant interpretation
98. Cardiac Involvement in Fabry Disease: JACC Review Topic of the Week
99. A novel tool for arrhythmic risk stratification in desmoplakin gene variant carriers
100. Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy:Results From SEQUOIA-HCM
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.